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Conformationally restricted enkephalin analogs containing E-cyclopropylphenylalanine (VEphe), [D-AlaZ, 
(2R,3S)-VEPh&,L&]enkephalin and its (2S,3R) isomer, were evaluated in receptor-binding assays using rat 
brain and in assays using muscle preparations. The (2S,3R) isomer was almost completely inactive in all 
assays. In contrast, the (2R,3S) isomer showed a very high affinity for the S and a very weak affinity for 
the ,u receptors in rat brain . The extent of S affinity and the selectivity of this isomer were almost equal 
to those of [D-Pen2,D-PenS]enkephalin. However, the (2R,3S) isomer was inactive in both the mouse vas 
deferens and guinea pig ileum assays, and showed no antagonistic activity in these tissues. These results 
indicate that the (2R,3S) isomer interacts with the 6 receptors in rat brain, but not with those in the mouse 
vas deferens, and they suggest hat the 6 receptors in the central and peripheral nervous systems are different 
from each other. 
Enkephalin analog; Conformational restriction, Opiate receptor; Receptor heterogeneity 
1. INTRODUCTION 
The incorporation of conformational con- 
straints into the opioid peptide enkephalins has 
been recognized as a useful structural modification 
to assess the stereochemical influence on the 
resulting biological profiles [l]. For example, sim- 
ple structural modification of an amino acid 
residue in a peptide sequence can elicit 
physicochemical and conformational changes uch 
as increased rigidity and hydrophobicity, restricted 
orientation of side chains, and possible induction 
of folding. The usefulness of such local conforma- 
tional restriction has been well demonstrated by 
the synthesis of the Z and E isomers of 
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dehydrophenylalanine4-enkephalins [2,3]. This line 
of study has also strongly suggested that receptor- 
specific and very selective enkephalin analogs can 
be designed to elucidate structure-activity relation- 
ships based on the existence of multiple opioid 
peptides and opiate receptors [l]. The presence of 
S and /I opiate receptors in brain has been 
demonstrated by examining the independent 
binding affinities using specific radiolabeled 
ligands [4,5]. Also, the heterogeneity of opiate 
receptors was confirmed in the peripheral tissues 
[6]; i.e. the mouse vas deferens (MVD) contains 
predominantly 6 receptors, and the guinea pig 
ileum (GPI) contains ,U receptors. 
1-Aminocyclopropanecarboxylic acids, namely, 
cyclopropylamino acids ( VAA: the inverted 
triangle, V , is used to designate ‘cyclopropyl’, and 
superscript, V E, . indicates the configuration about 
the cyclopropane ring), are structurally constrain- 
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Fig. 1. Chemical structure of [D-Ala’, VEPhe4,Leu5]- 
enkephalin. 
ed amino acids. The orientation of the p- 
substituents in V AA is restricted rigidly to only 
two possible values (0 and 120°) of the x1 angle, 
corresponding to the Z and E configurations, 
respectively. Incorporation of VAA into a peptide 
chain will effectively constrain its conformation 
due to the small q5 and $ angles at V AA conforma- 
tional energy minima. We have previously 
reported the synthesis of enkephalin analogs con- 
taining cyclopropylphenylalanine ( V Phe) in the E- 
(2R,3S) and E-(2S,3R) configurations (fig.1); 
namely, [D-Ala2,(2R,3S)- VEPhe4,Leu5]- and [D- 
Ala2,(2S,3R)- VEPhe4,Leu5]enkephalins [7]. It was 
expected that the incorporation of VEPhe into 
enkephalin would fix several of its conformational 
parameters thereby restricting severely its 
molecular shape and allowing it to recognize and 
bind selectively to one of the multiple opiate recep- 
tors. Unfortunately, these analogs were completely 
inactive in both the MVD and GPI biological 
assays [7]. Surprisingly, however, in a preliminary 
binding assay using rat brain membranes, we have 
found that the (2R,3s) isomer exhibits a high S 
receptor affinity with a very high selectivity. Here, 
we thus wish to report in detail the receptor- 
binding results of these VEPhe4-enkephalins in rat 
brain, and the results of biological assays for the 
evaluation of possible antagonistic activity in 
MVD and GPI. 
2. MATERIALS AND METHODS 
2.1. Peptides 
The synthesis of [D-Ala2,(2R,3S)- or 
(2S,3R)- VEPhe4,Leu5]enkephalin was reported 
previously [7,8]. [D-Ala2,D-Let?]enkephalin 
(DADLE) and [D-Ala2,MePhe4,Gly-ol’lenke- 
phalin (DAGO) were purchased from Sigma 
(St. Louis, MO). [D-Pen’,D-Per?]enkephalin 
(DPDPE) was purchased from Bachem (Buben- 
72 
dorf, Switzerland) and was utilized only for the 6 
receptors in both binding and biological assays 
because of its extremely low affinity for the ,u 
receptors. 
2.2. Receptor-binding assays 
Receptor-binding assays using rat brain mem- 
brane preparations were carried out essentially as 
in [9]. [3H]DADLE (41.8 Ci/mmol, Amersham) 
and [3H]DAG0 (42 Ci/mmol, Amersham) were 
used as tracers specific for the 6 and p receptors, 
respectively, at a final concentration of 0.25 nM. 
[3H]DPDPE (35 Ci/mmol) was obtained from 
Amersham. Incubations were carried out for 
60 min at 25°C in 50 mM Tris-HCl buffer (pH 7.4) 
containing bacitracin (100 pg/ml) as an enzyme in- 
hibitor . 
2.3. Biological assays 
Biological assays using the electrically 
stimulated smooth muscle preparations of MVD 
and GPI were performed essentially as in [lo]. 
Standard compounds (DADLE for MVD, and 
normorphine for GPI) were assayed in each 
preparation to permit estimation of relative 
potencies. 
In order to examine the effectiveness of 
(2R,3S)- VEPhe4-enkephalin (0.01-l PM) as an 
antagonist against DADLE in MVD and normor- 
phine in GPI, the assay was carried out essentially 
as described in [l 11. 
3. RESULTS AND DISCUSSION 
The (2R,3S) and (2S,3R) isomers of [D- 
Ala2, VEPhe4,Leu5]enkephalin were firstly re- 
examined for their inhibitory effects on the elec- 
trically stimulated contractions of MVD and GPI 
using DADLE as a standard (table 1). Both 
isomers were found to be almost completely inac- 
tive as reported in [7]. When they were evaluated 
in the radioligand-binding assays using rat brain 
membrane preparations, the (2S,3R) isomer, as in 
the biological assays, showed no activity, but the 
(2R,3s) isomer exhibited a very high affinity for 
the 6 receptors (Ki = 13 nM) using [‘HIDADLE as 
tracer (table l), although it was almost lo-fold less 
active than DADLE. Since the affinity of this 
isomer for the p receptors was extremely weak (Ki 
= 3290 nM) using t3H]DAG0 as tracer (table l), 
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Table 1 
Biological activities of enkephalin analogs in the mouse vas deferens (MVD) and 
guinea pig ileum (GPI) assays, and receptor-binding affinities in rat brain 
Biological assays Binding assays 
GO MM) Ki WI) 
MVD GPI t3H]DADLE [3H]DAG0 
(2R,38) isomer 2000 3700 13.0 3290 
(2S,3R) isomer 5800 14000 2560 1960 
DADLE 0.51 46.1 1.37 12.9 
DPDPE 3.78 a 10.7 NDa 
(2. 19)b (6&b 
a Not determined 
b Values from [ 121 
the receptor selectivity ratio, Ki([3H]DAGO)/ 
Kr([‘H]DADLE), was calculated to be about 250. 
This ratio is very high as compared with that of the 
6 ligand DADLE (ratio = 9.5, calculated from 
table 1). It is also of note that the selectivity of the 
(2R,3S) isomer for the 6 receptors in rat brain is 
almost equal to the reported selectivity of the 
standard S ligand DPDPE [12]. 
The results in table 1 raise a fundamental ques- 
tion about the activity of the (2R,3s) isomer, since 
there is a distinct discrepancy between the results 
for the S receptors in rat brain and in MVD. The 
(2R,3S) isomer is active in rat brain, but inactive in 
MVD. Since it is generally thought that the S recep- 
tors in rat brain and MVD are similar [6], we 
thought that the (2R,3s) isomer might have an- 
tagonistic activity at the S receptors in MVD; 
however, it showed no antagonistic activity in 
either the MVD or the GPI assays. The (2R,3S) 
isomer had no effects on the agonist action of 
DADLE in MVD and of normorphine in GPI at 
any concentration examined (0.01-l PM). Thus, it 
is more likely that the (2R,3S) isomer of 
V EPhe4-enkepha1in clearly distinguishes between 
the S receptors in the central and peripheral ner- 
vous systems, and that the 6 receptors in rat brain 
differ from those in MVD. 
For comparison, the most frequently utilized 6 
ligand to date, DPDPE, was tested together in the 
[3H]DADLE and MVD assays. In the binding 
assay, DPDPE was almost lo-fold less active than 
DADLE (table 1) as reported by others [12]. 
However, DPDPE displayed a concentration- 
response curve very similar to that of the (2R,35’) 
isomer, showing almost the same affinity as the 
(2R,3s) isomer for the 6 receptors in rat brain. On 
the other hand, DPDPE was highly active in the 
MVD assay (I& = 3.78 nM) despite the inactivity 
of the (2R,3S) isomer in this tissue. Obviously, 
DPDPE does not discriminate between the 6 recep- 
tors in rat brain and MVD. 
The (2R,3s) isomer and DPDPE were also 
evaluated in rat brain using [3H]DPDPE as a 
tracer. It was found that the (2R,35) isomer (1C50 
= 16.8 nM) and DPDPE (12.6 nM) were almost 
equally active also in this S-binding assay, confirm- 
ing the result of the t3H]DADLE-binding assay 
described above. 
In conclusion, the present study strongly sug- 
gests that the 6 receptors in rat brain and MVD 
possess slight structural differences that only [D- 
A1a2,(2R,3S)- VEPhe4,Leu5]enkephalin can re- 
cognize. These conclusions raise a number of ques- 
tions, such as (i) what is the biological activity of 
this analog in rat brain? (ii) Why is the compound 
active only in brain? Further studies to answer 
these and other questions are in progress in our 
laboratory. 
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